ARTICLE | Product Development
Biopharmas leading orphan drug approvals: Data Byte
BMS tops the chart, followed by Roche and Novartis
July 23, 2021 1:02 AM UTC
Updated on Oct 14, 2022 at 6:12 PM UTC
Though rare diseases can offer opportunities for small and mid-sized biotechs to retain ownership of their programs, pharmas still occupy eight of the top 10 spots for most orphan drug approvals.
Bristol Myers Squibb Co. (NYSE:BMY) tops the chart, with the largest number of orphan drug approvals in the past four and half years, at 32. ...